Medicines Shortages: A Growing Crisis in Supply Chains

In a quiet pharmacy in North London, the shelves typically lined with familiar brands and generics stood starkly bare. For weeks, Emily, a mother of two, had battled anxiety over her son’s ADHD medication, which had become elusive amid a civil service alert warning of shortages. A week later, while visiting her GP, the doctor offered a sympathetic nod and a different prescription—a bandaid solution that would ultimately prove inadequate. This dilemma is not simply a local issue; it has become emblematic of a larger, structural crisis rippling through pharmaceutical markets worldwide.

The Current Picture

Reports of medicines shortages have surged dramatically since 2021, with the number of notifications to the government increasing from an average of 82 per month to about 137 by 2023—a staggering 70% rise. According to the Department of Health, this alarming trend can be traced to multiple factors:

• Shortages of raw materials and packaging
• Geopolitical tensions, amplified by events like Brexit
• Disruptions from the COVID-19 pandemic, resulting in an overstressed supply chain

Although recent data from the government’s Discontinuation and Shortages (DaSH) portal indicates a decrease in monthly supply notifications since January 2025, experts remain cautious. Mark Dayan, Brexit programme lead at the Nuffield Trust, described the situation as “an international phenomenon,” highlighting similar reports of shortages in countries such as Canada and Australia. “We cannot overlook the inherent fragility in manufacturing caused by prolonged pressure on generics pricing,” he added.

Impact on Pharmacists and Patient Safety

The repercussions of these shortages extend beyond empty shelves. In a survey conducted by the Royal Pharmaceutical Society (RPS), over half of the 3,665 pharmacists reported a direct impact on their mental well-being due to the stress of managing shortages. This revelation has raised serious concerns about patient safety, particularly in vulnerable populations.

A troubling narrative unfolded in December 2024 when coroners reported patient fatalities linked to ADHD and epilepsy medication shortages. “For families already struggling with medical complexities, these shortages can feel like a death sentence,” remarked Dr. Helen Turner, a pediatrician in Manchester.

The All-Party Parliamentary Group on Pharmacy, in a July 2025 report, laid bare the magnitude of the issue, branding it a “chronic, structural challenge.” The inquiry emphasized the urgency for patient input and called for innovative measures to alleviate this growing crisis.

Enabling Pharmacists to Do More

Community pharmacists frequently find themselves at the frontlines of this crisis. Often blamed for the shortages, they are not adequately equipped to rectify the situation. Sonya Mitchell, Senior Policy Officer at Community Pharmacy England, stated, “Pharmacists are effectively the backbone of the healthcare system, yet they are forced to grapple with a crisis not of their making.” Data reveals that many pharmacists spend an average of two to five hours weekly dealing with supply issues.

In September 2025, the Department of Health announced plans for a consultation aimed at empowering pharmacists to supply alternative medication formulations when standard options are unavailable. “This could have immediate benefits for patients waiting for critical medications,” noted Alwyn Fortune of the RPS, who welcomed the initiative as essential. However, the proposal has drawn criticism for not addressing the complex nature of substitutions required for certain medications, particularly in ADHD treatments.

Manufacturing and Demand Forecasting

Manufacturing challenges constitute 60% of the supply chain issues, according to Ken Pullman, director of medicines policy and strategy at NHS England. “Unexpected changes in demand further complicate matters,” he noted, suggesting a need for improved data visibility and sharing. This point aligns with a report by the Association of the British Pharmaceutical Industry, indicating potential improvements through advanced forecasting aided by AI technologies.

Government Proposals and Industry Responses

The government’s proposals to tackle supply chain issues have received mixed reactions. One major initiative focuses on increasing compliance with eight-week buffer stock targets for secondary care. However, many experts, such as Ross Maclagan of the ABPI, express skepticism, cautioning against a one-size-fits-all approach to stockpiling. “Fine-tuning the supply chain is key; merely boosting buffer stocks can create systemic inefficiencies,” he noted.

Investing in domestic manufacturing has also emerged as a focal point in government discussions, yet the viability of producing all necessary medications locally remains a topic of contention. “We need targeted investments focused on innovations rather than generic products,” Maclagan argued. “The complexity of the supply chain means a blanket approach risks oversimplifying a deeply intricate issue.”

Challenges on the Horizon

Looking ahead, the landscape presents multiple hurdles. Dayan warned of potential impacts stemming from shifts in EU procurement strategies, which might prioritize local purchasing, heightening tensions between the UK and its trading partners. Furthermore, tariffs imposed by the Biden administration could elevate costs for imported medications, exacerbating existing shortages and posing additional risks to an already fragile system.

Experts recommend addressing the broader context of medicines security, balancing investments in domestic manufacturing with the necessity of maintaining strong trade relationships. “The challenge is not only about what we produce but how we ensure continuous collaboration across borders,” remarked Mark Samuels, chief executive of Medicines UK.

As the situation develops, it is clear that the current upheaval reflects deeper societal issues intertwined with healthcare infrastructure. If the lessons learned from the COVID-19 pandemic illustrate anything, it is that resilient systems can be a matter of life and death. The question now is whether the measures proposed will be enough to restore integrity and reliability to the pharmaceutical supply chain.

Source: pharmaceutical-journal.com